A Phase IIb, randomized, double blind, placebo controlled, dose ranging study to assess the effect of RPL554 in patients with moderate to severe COPD

Trial Profile

A Phase IIb, randomized, double blind, placebo controlled, dose ranging study to assess the effect of RPL554 in patients with moderate to severe COPD

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs RPL 554 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Verona Pharma
  • Most Recent Events

    • 31 Mar 2018 This trial has been completed in Czech Republic (End date: 2018-02-15).
    • 26 Mar 2018 According to an Arix Bioscience media release, Dave Singh, M.D., Professor of Clinical Pharmacology and Respiratory Medicine, University of Manchester is a principal Investigator of the study.
    • 26 Mar 2018 Results presented in an Arix Bioscience Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top